As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at personal care stocks, starting with Edgewell Personal Care (NYSE: EPC).

While personal care products may seem more discretionary than food, consumers tend to maintain or even boost their spending on the category during tough times. This phenomenon is known as "the lipstick effect" by economists, which states that consumers still want some semblance of affordable luxuries like beauty and wellness when the economy is sputtering. Consumer tastes are constantly changing, and personal care companies are currently responding to the public’s increased desire for ethically produced goods by featuring natural ingredients in their products.

The 9 personal care stocks we track reported a satisfactory Q2. As a group, revenues beat analysts’ consensus estimates by 1.7% while next quarter’s revenue guidance was 1.5% above.

Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 5.7% since the latest earnings results.

Edgewell Personal Care (NYSE: EPC)

Boasting brands such as Banana Boat, Schick, and Skintimate, Edgewell Personal Care (NYSE: EPC) sells personal care products in the skin and sun care, shave, and feminine care categories.

Edgewell Personal Care reported revenues of $570.1 million, up 1.7% year on year. This print fell short of analysts’ expectations by 1.2%. Overall, it was a slower quarter for the company with a significant miss of analysts’ organic revenue estimates and a miss of analysts’ EBITDA estimates.

"Our third quarter results represent an important step forward in our fiscal 2026 progression, with organic net sales returning to growth, meaningful improvement in North America, and adjusted EPS and adjusted EBITDA ahead of expectations," said Rod Little, Edgewell's President and Chief Executive Officer.

The market seems disappointed with the results as the stock is down 3.4% since reporting and currently trades at $27.57.

Read our full report on Edgewell Personal Care here, it’s free.

Best Q2: e.l.f. Beauty (NYSE: ELF)

Short for "eyes, lips, face", e.l.f. Beauty (NYSE: ELF) is a developer of high-quality beauty products at accessible price points.

e.l.f. Beauty reported revenues of $479.4 million, up 35.5% year on year, outperforming analysts’ expectations by 11%. The business had a stunning quarter with a beat of analysts’ EPS estimates and an impressive beat of analysts’ gross margin estimates.

e.l.f. Beauty pulled off the biggest analyst estimate beat, fastest revenue growth, and highest full-year guidance raise among its peers. The market seems happy with the results as the stock is up 14.1% since reporting. It currently trades at $98.58.

Is now the time to buy e.l.f. Beauty? Access our full analysis of the earnings results here, it’s free.

Weakest Q2: Nature's Sunshine (NASDAQ: NATR)

Started on a kitchen table in Utah, Nature’s Sunshine (NASDAQ: NATR) manufactures and sells nutritional and personal care products.

Nature's Sunshine reported revenues of $117 million, up 1.9% year on year, falling short of analysts’ expectations by 5.4%. It was a disappointing quarter as it posted a significant miss of analysts’ EBITDA estimates and a significant miss of analysts’ EPS estimates.

Nature's Sunshine delivered the weakest performance against analyst estimates and weakest full-year guidance update of the whole group. As expected, the stock is down 29.5% since the results and currently trades at $14.34.

Read our full analysis of Nature's Sunshine’s results here.

Inter Parfums (NASDAQ: IPAR)

With licenses to produce colognes and perfumes under brands such as Kate Spade, Van Cleef & Arpels, and Abercrombie & Fitch, Inter Parfums (NASDAQ: IPAR) manufactures and distributes fragrances worldwide.

Inter Parfums reported revenues of $341 million, up 2.1% year on year. This result beat analysts’ expectations by 0.6%. Zooming out, it was a slower quarter as it logged a significant miss of analysts’ gross margin estimates and full-year revenue guidance missing analysts’ expectations.

The stock is down 10.7% since reporting and currently trades at $114.77.

Read our full, actionable report on Inter Parfums here, it’s free.

Medifast (NYSE: MED)

Known for its Optavia program that combines portion-controlled meal replacements with coaching, Medifast (NYSE: MED) has a broad product portfolio of bars, snacks, drinks, and desserts for those looking to lose weight or consume healthier foods.

Medifast reported revenues of $76.38 million, down 27.6% year on year. This print topped analysts’ expectations by 5.1%. Overall, it was a stunning quarter as it also produced EPS guidance for next quarter exceeding analysts’ expectations and a beat of analysts’ EPS estimates.

Medifast achieved the highest guidance raise but had the slowest revenue growth among its peers. The stock is up 19.3% since reporting and currently trades at $11.62.

Read our full, actionable report on Medifast here, it’s free.

Market Update

Over the past year, investors have been forced to repeatedly answer the same question: what is the market’s biggest risk? The answer has changed several times, and each shift has reshaped market leadership.

Late in 2025 and early 2026, artificial intelligence became the market’s primary uncertainty. Investors questioned whether AI would erode software pricing power and weaken competitive moats as AI made it easier to replicate once-differentiated products.

By the spring, technology took a back seat to geopolitics. The U.S. conflict with Iran briefly became the market’s dominant narrative, raising concerns about oil prices, inflation, and global growth. But as energy markets remained orderly and fears of a prolonged supply disruption faded, investors quickly turned their focus back to fundamentals.

Want to invest in winners with rock-solid fundamentals? Check out our 9 Best Market-Beating Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.